Urogenital Tract Infection

Original Articles

The Feasibility of Radical Prostatectomy for Medication Refractory Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Seung Chan Jeong; Urogenit Tract Infect 2022;17(3):76-80. Published online December 31, 2022; DOI: https://doi.org/10.14777/uti.2022.17.3.76

Abstract PDF PubReader ePub: Purpose: The purpose of this study was to compare the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) scores of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) given pharmacological treatment with those who additionally had prostate cancer and underwent surgical treatment.
Materials and Methods: From January 2000 to March 2021, a total of 7,650 patients were diagnosed with chronic prostatitis (N41.1) at our hospital, of which 234 patients were additionally diagnosed with prostate cancer. After excluding patients with severe benign prostatic hyperplasia (＞100 g)-related lower urinary tract symptoms or neurological and psychiatric abnormalities, or advanced prostate cancer, 52 patients undergoing pharmacological treatment with a combination of drugs and 20 patients who underwent radical prostatectomy due to additional prostate cancer were included in the analysis. The NIH-CPSI scores of the two groups were compared at the first outpatient visit, 3 months, and 6 months after the first visit. The p-values were calculated using the Mann-Whitney U test, and the Wilcoxon signed rank test.
Results: Patients who underwent radical prostatectomy for prostate cancer showed significant reductions in the voiding and quality of life scores in the NIH-CPSI, but not the pain score at 3 months. After 6 months, there was a significant decrease in the overall NIH-CPSI. On the other hand, in the group on pharmacological therapy, the decrease was statistically significant only in the voiding score at 6 months. However, in the surgery group, 3 patients were found to be suffering from urinary incontinence, and 7 patients from erectile dysfunction.
Conclusions: Radical prostatectomy, therefore, appears to be a promising treatment that can be carefully considered for patients with refractory CP/CPPS who do not receive adequate treatment and thus have a poor quality of life.

34 View
0 Download

Pilot Study of Cystochon^® (Cranberry Extract, Chondroitin Sulfate, and Hyaluronic Acid Complex) in Interstitial Cystitis/Bladder Pain Syndrome: Kwang Taek Kim, Jeong Woo Lee, Hyun-Sop Choe; Urogenit Tract Infect 2022;17(2):36-41. Published online August 31, 2022; DOI: https://doi.org/10.14777/uti.2022.17.2.36

Purpose: This study examined whether Cystochon^® (cranberry extract, chondroitin sulfate, and hyaluronic acid complex) effectively improves the symptoms and problems of interstitial cystitis/bladder pain syndrome (IC/BPS) patients.
Materials and Methods: From December 2021 to May 2022, the medical records of IC/BPS patients who visited St. Vincent’s Hospital, Kyung Hee University Medical Center, or Gachon University Gil Medical Center were collected. For the treatment of IC/BPS, the patients were given pentosan polysulfate (PPS) for 12 weeks, with Cystochon^® then added and maintained for an additional eight weeks. The OʼLeary–Sant symptom and problem index (Interstitial Cystitis Symptom Index [ICSI], Interstitial Cystitis Problem Index [ICPI]) was used to measure the treatment response.
Results: After 12 weeks of PPS treatment, ICSI and ICPI improved in all patients. After adding Cystochon^® for eight weeks, the ICSI and ICPI indicators improved further. In the ICSI category, significant improvement in symptoms was confirmed in the total ICSI score, particularly in the Q4 (pain-related) questionnaire after adding Cystochon^®. In the ICPI category, significant problem improvement was confirmed in the total ICPI score, particularly in the Q1 (frequent urination) and Q4 (pain-related) questionnaires. Although not statistically significant, the remaining indicators generally tended to improve.
Conclusions: The orally administered combination of cranberry extract, chondroitin sulfate, and hyaluronic acid (Cystochon^®) may have a clinically positive effect in patients with IC/BPS. Better clinical improvement can be expected when it is added to the PPS treatment, especially in the category of bladder pain.

Citations

Citations to this article as recorded by

Anti-inflammatory effect of sea buckthorn in an HCl-induced cystitis rat model
Hyun Suk Yoon, Juyeon Yu, Shinhoon Kang, Hana Yoon
Investigative and Clinical Urology.2025; 66(1): 67. CrossRef
Pharmacological Properties of Shionone: Potential Anti-Inflammatory Phytochemical against Different Diseases
Varun Jaiswal, Hae-Jeung Lee
Molecules.2023; 29(1): 189. CrossRef

45 View
0 Download
2 Crossref

First
Prev
Page of 1
Next
Last

Search